| The incidence rate of pulmonary carcinoma is increasing gradully. Operation is still main therapy for it. But majority of them belone intermediate stage or advanced stage already and missed the opportunity of routine operation when they were final diagnosised .Nonsmall-cell lung cancer is insensitivity to chemotherapy.Accordingly the application of Endocare Targeted Cryoablation to degrade nodule burden and improve the symptoms remarkably and then match chemotherapy not only can enhance the immunity ,but also raise chemotherapy therapeutic efficacy and prolong live time .Objecctive: To compare the response rate, median time to progression (TTP) , clinical benefit and immunity in patients with advanced NSCLC, treated with Endocare Targeted Cryoablation plus vinorelbine and cisplatin (NP ) or simple NP.Methods: 80 histology or cytology confirmed stage III and IV NSCLC patients were research after stratification, either Arm A: NP plus Endocare Targeted Cryoablation ( n=40; vinorelbine 25mg/m2 on day 1 and day8, cisplatin 25mg/ m2 on days 1 to 3 every 3 weeks for 2 cycles after therapy with Endocare Targeted Cryoablation 1 or 2 weeks) or Arm B: simple NP ( n=40; vinorelbine 25mg/m2 on day 1 and day8, cisplatin 25mg/ m2 on days 1 to 3 ) every 3 weeks for 2 cycles, according to the response after the second cycles, i.e. CR,PR,SD continue to receive treatment; while PD stop treatment.Results: (1),This study suggested that the method of helium-argon knife and programme NP complete remission rate was 10 percent, partial remission rate was 57.5%, stable rate was 30 percent, the progress rate was 2.5 per cent. programme for NP single,the complete remission rate was five percent. Partial remission rate was 35 percent, stable rate was 45 percent, the progress rate was 15 per cent. In the progrom of Endocare targeted cryoablation and NP chemotherapy ,MST (median survival time) for the group of treatment was 10 months.The MST for programme for NP single was 8 months. TTP for Endocare targeted cryoablation and NP chemotherapy was four months. TTP for group of NP chemotherapy alone was three months.(2),Age, gender, pathological types had no obviously effect on the efficacy of Programme of endocare targeted cryoablation plus NP (Vinorelbine + cisplatin) chemotherapy therapy in the treatment of NSCLC.Clinical stage and size of lesions had influence on the programme of endocare targeted cryoablation therapy Plus NP Programme (Vinorelbine + cisplatin) in the treatment of NSCLC.Complete remission rate ofⅢperiod was 16.67 percent, partial remission rate was 62.5%, stable rate was 16.67 percent, Progress rate was 4.16 percent.Cases ofⅣstage had no complete remission. Partial remission rate was 50%, stable rate was 50%, It had no progress cases.The efficient ofⅢstage was 79.17 percent, inefficient was 20.83%; The efficient ofⅣstage was 50%,The size of lesion had effect on the efficacy of Endocare targeted cryoablation and programme of NP (Vinorelbine + cisplatin) chemotherapy in the treatment of NSCLC. If the diameter of progress was less 6cm,the complete remission rate was 11.12%.Partial remission rate was 58.33 percent, stable rate was 27.77 percent, and progress rate was 2.78 percent. If the diameter of progress was more than 6cm,the complete remission rate was 0 percent, partial remission rate was 50%, stable rate was 50 percent. If the diameter of progress was less 6.0 cm ,the efficiency was 69.45%, inefficiency was 30.55%. the diameter was more than 6 cm in the four cases of, of which the efficiency was 50 percent, the inefficiency was 50%.The P of all of above was less than 0.05, there are significant differences.(3),Lesions affecting the size of the Endocare targeted cryoablation plus NP chemotherapy in the treatment of advanced NSCLC survival of the time factor.≤6 cm diameter of the one-year survival rate of 55.55 percent; 1, -2, the survival rate of 19.45 percent, above the 2-year survival rate of 25 percent; diameter> 6 cm 1-year survival rate was 75 percent, one-year survival rate for the year -2 0 percent, 2-year survival rate of more than 25 percent. Above P less than 0.05, there are significant differences.(4),Age, gender, pathological type and stage and size of lesions on both endocare targeted cryoablation therapy plus NP chemotherapy in the treatment of NSCLC time to disease progression (TTP) had no significant impact.(5),Less than 6.0 cm in diameter hockey coverage over 1.0 cm of 27.78 percent, ice hockey coverage of over 80 percent of the 61.11 percent, ice hockey coverage of between 70% -80% of 8.33%, ice hockey coverage is less than 70 percent of the 2.78 percent, the significant efficiency 96%. Diameter greater than 6 cm of ice hockey coverage of over 80 percent of the 25 per cent, ice hockey coverage of between 70% -80% to 25%, ice hockey coverage is less than 70 percent of the 50 per cent of the total effective rate is 62.60 percent. Above P less than 0.05, there are significant differences.(6),Endocare targeted cryoablation plus NP Programme (Vinorelbine + cisplatin) chemotherapy therapy and treatment of a blood test taken after the cycle of T-cell subsets CD3 +, CD4 +, CD8 +, CD4 + / CD8 +,. CD3 + respectively before and after treatment for 41.01 +4.78,54.26 +4.57, before and after treatment CD4 + respectively 24.32 +3.33,36.12 +2.97, before and after treatment CD8 + respectively 35.54 +3.67,25.23 +3.21, before and after treatment CD4 + / CD8 + respectively 0.68 +0.02,1.44 +0.07. P less than 0.05, there are significant differences.(7),Endocare targeted cryoablation therapy plus NP Programme (Vinorelbine + cisplatin) chemotherapy with the simple NP chemotherapy for advanced non-small cell lung cancer patients after coughing, hemoptysis symptoms such as chest pain and ease the rates were 92% and 70%.(8),Endocare targeted cryoablation plus NP chemotherapy treatment and the NP simple bone marrow toxicity of chemotherapy in the treatment of NSCLC, endocare targeted cryoablation therapy joint NP chemotherapy to reduce the incidence of interleukin 80 percent, platelet decline in the incidence of 25 percent pure NP chemotherapy, interleukin reduce the rate of 100% , Platelet decline in the incidence of 55 percent. Digestive system toxicity: the Endocare targeted cryoablation plus NP chemotherapy nausea and vomiting rate was 30 percent, only NP chemotherapy, nausea and vomiting rate was 50 percent.Conclusion: (1),Endocare targeted cryoablation therapy plus NP (Vinorelbine + cisplatin) chemotherapy for the treatment of advanced non-small cell lung cancer and a partial reduction of the overall disease control mutual synergies, to a certain extent, help to strengthen anti - Tumors, reduce relapse rates and transfer rates, so that surgery can not be part of the advanced non-small cell lung cancer patients improve the quality of life and extended survival period.( 2 ),Endocare targeted cryoablation therapy targeted plus NP chemotherapy can improve the body's anti-tumor immunity and inhibit tumor growth and removal of the remnants of lung cancer cells and improve the effectiveness of treatment, to further extend survival in patients with a very positive role.( 3 ),Endocare targeted cryoablation therapy targeted plus NP programme (Vinorelbine + cisplatin) chemotherapy in the treatment of NSCLC the effect of the phases, the sooner that the effect of significantly higher efficiency as possible.(4),Endocare targeted cryoablation Plus NP effect of chemotherapy affected the main factors for the cancer lesion size, coverage of the ice hockey. The smaller the size of lesions (greater than 2.0 cm in diameter and less than 6 .0cm between) the higher the ice hockey coverage, and the NP in the treatment of the significant higher efficiency, better effect.(5),Gender, pathological types of endocare targeted cryoablation therapy of the NP and the efficacy of chemotherapy survival rates were not significantly affected.
|
PDF Full Text Request